Tolemy Bio
- Company typePrivate
- Founded2024
- HeadquartersCambridge, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
Tolemy Bio firmographics
Firmographics- Name
- Tolemy Bio
- Legal name
- Tolemy Bio Ltd
- Website
- https://tolemy.bio
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Tolemy Bio industry classification
Industry- Product category
- Computational Biology Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)
Keywords
Where Tolemy Bio is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Tolemy Bio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Commercial partnerships / co-developed services (e.g., aiMOS™ with GeminiBio): Revenue appears to be generated through B2B commercial partnerships and co-developed services targeting cell therapy manufacturers. The aiMOS™ service is offered to customers to improve cell therapy performance, reduce costs, and support scaling — consistent with a managed-services or professional-services revenue motion alongside any underlying platform licensing.
- Pre-revenue / partner-development phase: Company is in active partner-acquisition mode ("We are looking for new partners and applications") suggesting revenue streams are not yet formalized; funding currently backs R&D rather than scaled monetization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based / Not publicly disclosed |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Tolemy Bio product offering
Product offeringCore offering
Tolemy Bio builds an AI-native virtual cell platform that serves as an intelligence layer to direct cellular systems for better therapeutic outcomes. The platform helps teams map, simulate, and improve living systems across Cell Biology, Advanced Therapeutics, and Bioprocessing. It also powers the aiMOS™ service, co-developed with GeminiBio, which uses AI and multi-omics data to optimize cell culture media supplements for cell therapy manufacturing.
Product overview
Tolemy Bio offers a single unified AI-native virtual cell platform (the "Tolemy Platform") that serves as the intelligence layer for therapeutic development and manufacture across Cell Biology, Advanced Therapeutics, and Bioprocessing. As a complement to this core platform, Tolemy Bio co-developed the aiMOS™ service with Gemini Bio, which leverages the platform's AI capabilities together with multi-omics data to optimize media supplements specifically for cell therapy manufacturing. Together, the Tolemy Platform provides the foundational virtual cell modeling and simulation capabilities, while aiMOS™ delivers an applied, co-branded offering targeting cell therapy media optimization within the broader bioprocessing and advanced therapeutics scope.
Differentiator
Problem solved
Functional benefit
Products and services
- Tolemy Platform The AI-native virtual cell platform for therapeutic development and manufacture. It serves as the intelligence layer to direct cellular systems for better therapeutic outcomes, spanning Cell Biology, Advanced Therapeutics, and Bioprocessing applications. Targeted at research and industry teams working on cell biology and bioprocessing.
- aiMOS™ A co-developed service with GeminiBio that leverages AI and multi-omics data to optimize media supplements for cell therapy manufacturing. Aims to improve cell therapy performance, reduce costs, and support scaling from research to commercialization. Targeted at cell therapy manufacturers and bioprocessing teams.
Quantifiable outcome
- Aims to improve cell therapy performance and reduce costs, and to support scaling from research to commercialization
- +1 more outcomes
Companies that use Tolemy Bio
Customer profileSegments3 records
Ideal customer profiles3 records
Tolemy Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature2 records
Tolemy Bio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- GeminiBioflagship commercial partnershipA collaboration between Tolemy Bio and California-based GeminiBio launched aiMOS™, a technology that leverages AI and multi-omics data to optimize media supplements for cell therapy manufacturing. The jointly offered service aims to improve cell therapy performance, reduce costs, and support scaling from research to commercialization.
Scale indicators5 records
Recent moves5 records
Expansion highlights5 records
Tolemy Bio competitors and assessment
Company assessmentEmerging players
- Deepcell: Deepcell uses AI and microfluidics to characterize single cells at high throughput, comparable to Tolemy in combining AI with cell-level biological data. Its focus is single-cell analysis rather than cell therapy process optimization.
- CytoReason: CytoReason builds AI models of the human cell for pharma R&D, using cell biology as its primary data domain. It is comparable to Tolemy in focusing on cell-level biological modeling, though its end-customers are pharma discovery teams rather than cell therapy manufacturers.
- Culture Biosciences: Culture Biosciences operates a cloud bioprocess development platform, combining experimentation with data infrastructure for bioprocess R&D. It is comparable to Tolemy in addressing bioprocess scale-up and data-driven optimization for cell-based manufacturing.
- Synthace: Synthace offers a cloud-based platform for automating and optimizing biological experiments, directly overlapping with Tolemy's mission of providing an AI-driven interface to design and control wet-lab biology.
- Owkin: Owkin applies AI to biomedical and clinical data for drug discovery and development. It is thematically adjacent in the AI-for-biology category and competes for the same enterprise biopharma customer base.
Direct peers
- Insitro: Insitro builds ML-driven models of human biology to accelerate drug discovery, a closely adjacent 'AI-native biology' play. Both companies pursue the same thesis that machine learning on biological data can transform therapeutic development.
- Cradle: Cradle applies AI/ML to biologics design and bioprocess optimization, directly overlapping with Tolemy's AI-for-biology and bioprocessing positioning. Both target the same bottleneck of using AI to design and optimize biological systems for therapeutic and industrial use.
Broad incumbents
- Schrödinger: Schrödinger applies physics-based computational modeling and ML to drug discovery and materials. Its physics-informed biology approach and AI-driven simulation tooling overlap conceptually with Tolemy's interdisciplinary software + physics + biology stack.
- Recursion Pharmaceuticals: Recursion is a publicly listed AI-for-drug-discovery incumbent combining high-throughput biology with ML. It operates in the same AI-native biology category as Tolemy but at substantially greater scale and capital intensity.
- Ginkgo Bioworks: Ginkgo is a publicly listed cell engineering and biosecurity platform. It competes in cell programming and bioprocess optimization — adjacent to Tolemy's cell biology and bioprocessing focus — and offers a much broader service portfolio.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Tolemy Bio social profiles
Digital presenceTolemy Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tolemy Bio leadership team
Management profileNumber of profiles
Profiles2 records
Tolemy Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tolemy Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tolemy Bio
What does Tolemy Bio do?
Tolemy Bio builds an AI-native virtual cell platform that serves as an intelligence layer to direct cellular systems for better therapeutic outcomes. The platform helps teams map, simulate, and improve living systems across Cell Biology, Advanced Therapeutics, and Bioprocessing. It also powers the aiMOS™ service, co-developed with GeminiBio, which uses AI and multi-omics data to optimize cell culture media supplements for cell therapy manufacturing.
Is Tolemy Bio a public or private company?
Tolemy Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Tolemy Bio founded?
Tolemy Bio was founded in 2024. It employs 1 to 10 people.
Where is Tolemy Bio based?
Tolemy Bio is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Tolemy Bio make money?
Two revenue lines are on record. Commercial partnerships / co-developed services (e.g., aiMOS™ with GeminiBio) is the primary driver. The others are pre-revenue / partner-development phase.
Who are Tolemy Bio's main competitors?
Emerging players on record are Deepcell, CytoReason, Culture Biosciences, Synthace and Owkin. Direct peers are Insitro and Cradle. Broad incumbents are Schrödinger, Recursion Pharmaceuticals and Ginkgo Bioworks.
Does Tolemy Bio have an API?
No public API is recorded for Tolemy Bio.
What industry is Tolemy Bio in?
Tolemy Bio's product category is Computational Biology Software. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.